Renaissance Capital logo

Treace Medical Concepts Priced, Nasdaq: TMCI

Makes a medical device system for the treatment of bunions.

Industry: Health Care

Latest Trade: $13.05 0.00 (0.0%)

First Day Return: +50.2%

Return from IPO: -23.2%

Industry: Health Care

We are a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions). We have pioneered our proprietary Lapiplasty 3D Bunion Correction System -- a combination of novel instruments, implants and surgical methods designed to improve the inconsistent clinical outcomes of traditional approaches to bunion surgery. Although bunions are deformities typically caused by an unstable joint in the middle of the foot that leads to a three-dimensional (3D) misalignment in the foot’s anatomical structure, the majority of traditional surgical approaches focus on correcting the deformity from a two-dimensional (2D) perspective and therefore fail to address the root cause of the disorder. To effectively restore the normal anatomy of bunion patients and improve clinical outcomes, we believe addressing the root cause of the bunion is critical and have developed the Lapiplasty System to correct the deformity across all three anatomic dimensions. Our mission is to be the leader in the surgical treatment of bunions by establishing the Lapiplasty System as the standard of care.
more less
IPO Data
IPO File Date 03/30/2021
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 11.3
Deal Size ($mm) $191
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/22/2021
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 11.3
Deal Size ($mm) $191
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
J.P. Morgan
Morgan Stanley
more
Company Data
Headquarters Ponte Vedra, FL, United States
Founded 2014
Employees 133
Website www.treace.com

Treace Medical Concepts (TMCI) Performance